Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
unknown
📅 Published: 2026-03-18 12:05
📰 Source: Yahoo
📝 Words: 41
📝 Article Content
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable ...
📄 Summary
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable ...
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:40
Updated At:
2026-03-20 04:09:40
Scraping Job ID:
N/A
Stock Mentions:
ALL - The Allstate Corporation
Relevance: N/A
MET - MetLife Inc.
Relevance: N/A